Months after its dozen scientists began working in secret on what’s been called “the most clever CRISPR gadget” so far, the latest company hoping to deploy genome-editing to cure diseases came out of stealth mode on Monday.

Beam Therapeutics, which registered as a corporation in Massachusetts in March and has been doing experiments since last year, is debuting as CRISPR companies are popping up like dandelions, but right out of the gate Beam stands out in a crowded field. Its three founders are among the world’s leading CRISPR’ers, Editas Medicine (EDIT) has an equity stake, and in addition to the $13 million it’s raised (from Arch Venture Partners and F-Prime Capital Partners), it has commitments for another $85 million.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy